WHO WE ARE
We get the right drug, to the right patient, at the right time.
To fundamentally change how diseases are diagnosed and treated. With our pioneering metabolomics platform and machine learning algorithms we produce “Biomarkers of Response” (BoR) to readily differentiate drug responders (R) from non-responders (NR).
We are building a BoR pipeline across therapeutics areas including cancer, neurodegenerative disease, immune response and more.